PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that the underwriters of its recently completed initial public
offering (IPO) have exercised in full their option to purchase an
additional 750,000 shares of common stock from Esperion to cover
over-allotments. The sale of the additional shares closed on July 11,
2013. Including proceeds from the sale of the additional shares, the net
proceeds to Esperion from the IPO are expected to be $72.8 million after
deducting underwriting discounts and commissions and estimated offering
expenses payable by Esperion.
Credit Suisse and Citigroup acted as joint book-running managers for the
offering. JMP Securities and Stifel acted as co-managers.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on June 25, 2013.
Copies of the final prospectus relating to the offering may be obtained
by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus
Department, One Madison Avenue, New York, NY 10010, by calling toll-free
(800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com;
or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, by email at batprospectusdept@citi.com,
or by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
BrewLife
Denise Powell
510.703.9491
dpowell@brewlife.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media